Li Shanto Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-11-2024
- Paid Up Capital ₹ 0.10 M
as on 02-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 02-11-2024
- Revenue 1885.70%
(FY 2023)
- Profit 288.87%
(FY 2023)
- Ebitda -758.41%
(FY 2023)
- Net Worth 66.93%
(FY 2023)
- Total Assets 1759.95%
(FY 2023)
About Li Shanto Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Sanjeev Kumar, Birendra Singh, Akash Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304PN2020PTC193291
- Company No.
193291
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Li Shanto Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Birendra Singh  | Managing Director | 24-Aug-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sanjeev Kumar | Director | 24-Aug-2020 | Current |
| Akash Kumar | Director | 24-Aug-2020 | Current |
| Vikash Singh | Director | 24-Aug-2020 | Current |
Financial Performance of Li Shanto Pharmaceuticals.
Li Shanto Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1885.7% increase. The company also saw a substantial improvement in profitability, with a 288.87% increase in profit. The company's net worth Soared by an impressive increase of 66.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Li Shanto Pharmaceuticals?
Unlock access to Li Shanto Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 01 Feb 2022 | ₹5.00 M | Open |
How Many Employees Work at Li Shanto Pharmaceuticals?
Li Shanto Pharmaceuticals has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Li Shanto Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Li Shanto Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
